Introduction
============

Prostate-specific antigen (PSA) testing has been widely used for prostate cancer (PCa) screening, and transrectal ultrasound (TRUS)-guided biopsies have been widely performed.[@b1-rru-9-187],[@b2-rru-9-187] However, even with the contemporary use of laterally directed extended TRUS-guided biopsies, the false-negative rate remains high.[@b3-rru-9-187] Patients whose condition was diagnosed as negative with a TRUS-guided biopsy have been considered for a repeat biopsy if the following findings are present: increased PSA levels; abnormal findings on digital rectal examination (DRE), TRUS, and magnetic resonance imaging (MRI); and a previous biopsy showing high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP).

HGPIN is defined as proliferation of the acini and ducts in epithelial cells, similar to PCa.[@b4-rru-9-187] The presence of HGPIN seen on sextant biopsy has been considered a strong predictor of PCa at repeat biopsy (45%[@b5-rru-9-187] and 35%[@b6-rru-9-187]). With octant biopsy, the rate of carcinoma seen on repeat biopsy for patients with HGPIN has decreased (19.9%[@b7-rru-9-187] and 12.6%[@b8-rru-9-187]). Merrimen et al reported that multifocal HGPIN was a significant risk factor for PCa in 12,304 men.[@b9-rru-9-187] Roscigno et al showed that the presence of two or more cores of HGPIN was a significant predictive factor for PCa at repeat saturation biopsy.[@b10-rru-9-187]

ASAP reflects a broad group of lesions of varying clinical significance, including lesions that mimic cancer and many lesions that demonstrate retrospectively focal carcinoma but contain insufficient cytological or architectural atypia to establish a definitive diagnosis of cancer.[@b11-rru-9-187] Previous studies suggested that, on average, 30%--40% (range: 17%--70%) of patients with ASAP harbor adenocarcinoma at a subsequent prostate biopsy.[@b12-rru-9-187],[@b13-rru-9-187] Accordingly, current American[@b14-rru-9-187] and European[@b15-rru-9-187] guidelines recommend immediate repeat biopsy within 3--6 months after an initial diagnosis of ASAP.

HGPIN (extended or two or more cores) and ASAP have been recognized as potential risk factors for PCa. However, the clinical meaning of HGPIN and ASAP seen on repeat saturation biopsy has not been adequately reported. Furthermore, Patel et al[@b16-rru-9-187] and Leone et al[@b17-rru-9-187] reported that cancer detected on repeat biopsy after a diagnosis of ASAP and HGPIN is rarely found to be high-grade cancer. Therefore, there is not enough evidence to support the use of saturation biopsy for HGPIN and ASAP. In a previous study, we conducted a saturation biopsy that required one biopsy core per milliliter of prostate volume,[@b18-rru-9-187] and we showed that there was a high mean number of biopsy cores per unit prostate volume of 1.06 core/mL. With this method, we can obtain a sufficient sample and precise diagnosis. Therefore, in this study, we evaluated whether the presence of HGPIN and ASAP at a previous biopsy is a positive predictor of PCa during transperineal template saturation biopsy (TTSB) and sought to determine the results of patients who have the findings of HGPIN and ASAP.

Patients and methods
====================

Patient selection
-----------------

Between January 2006 and January 2015, 967 patients received a TRUS-guided biopsy in our hospital due to the suspicion of PCa. A TRUS-guided biopsy was performed according to the procedure of our previous report.[@b2-rru-9-187] The condition of 432 patients (44.7%) was diagnosed as negative. Among these patients, 23 (2.3%) and 17 (1.6%) patients were diagnosed with HGPIN and ASAP, respectively. We recommended a repeat biopsy for all patients with HGPIN and ASAP. Consequently, 18 and 12 patients with HGPIN and ASAP, respectively, underwent a repeat saturation biopsy. Patients with HGPIN were included in the HGPIN diagnostic category. Patients with ASAP alone or ASAP with HGPIN were included in the ASAP diagnostic category.[@b9-rru-9-187]

Between July 2006 and August 2015, we offered TTSB to patients who were considered to need a repeat prostate biopsy when the following clinical factors were present: increased PSA levels; abnormal findings on DRE, TRUS, or MRI; and a previous biopsy that showed HGPIN and/or ASAP. The number of TRUS-guided biopsies at TTSB was 1--5 negative biopsies (median: 1), and the median time from the last TRUS-guided biopsy to TTSB was 651 days (range, 84--3,522). A total of 135 consecutive patients who received repeated TTSB were enrolled in this study. Then, we retrospectively analyzed the data. Two genitourinary pathologists established all pathologic diagnoses. The institutional review board of Nara Medical University approved this study.

TTSB procedure
--------------

We previously reported on the TTSB method that we used in this study.[@b18-rru-9-187] A transrectal probe (Toshiba Medical, Tochigi, Japan) that was attached to a brachytherapy stepping unit (AccuSeed, Bedfordshire, UK) was inserted into the rectum. The low-echoic area was estimated, and the prostate volume was calculated by using the following formula: length × width × height × 0.5236. The space between biopsy cores in a row was uniformly 5 mm from right to left in the longitudinal view, except for the area nearest to and around the urethra. When a sufficient sample was not taken from the apex of the bladder because of large prostate volume, we considered using an additional core to take the sample from a point near the bladder. To achieve "saturation biopsy," one biopsy core per milliliter of prostate volume was required. The biopsy was performed by using an 18-gauge, 25-cm-long biopsy gun (Bard, Covington, GA, USA).

For patients with multiple PSA measurements prior to the saturation biopsy, we used the most recent value before the saturation biopsy date. Insignificant cancer was defined as a clinically insignificant Gleason score (GS) of 6, maximum tumor length of \<4.5 mm, and total tumor length of \<5.5 mm based on a report by Epstein et al.[@b19-rru-9-187]

Statistical analysis
--------------------

The statistical analysis was performed with SPSS for Windows (version 20.0; IBM, Armonk, NY, USA). Mann--Whitney *U* test was used for continuous variables, and chi-square test was used for categorical variables. A binary logistic regression analysis was used to estimate the independent parameters of positive TTSB. The cutoff value was determined as the point closest to the upper left-hand corner of the receiver operating characteristic curve. A univariate analysis was applied to isolate variables with a significant value of *P*\<0.05. Variables that were found to predict PCa in the univariate analysis were included in the multivariate analysis. A *P* value \<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

The patients' characteristics are summarized in [Table 1](#t1-rru-9-187){ref-type="table"}. The numbers of cores obtained from the last TRUS-guided biopsies in the HGPIN (*P*=0.004) and ASAP groups (*P*=0.04) were significantly higher than those in the benign group. The PSA levels of the HGPIN (*P*=0.003) and ASAP (*P*=0.04) groups were significantly lower than those of the benign group. The PSA velocity in the HGPIN group (*P*=0.02) was significantly lower than that of the benign group. No patient had ASAP and HGPIN simultaneously.

TTSB results
------------

The median number of cores that were taken with TTSB was 37 (range: 16--75), and the median number of biopsy cores per prostate volume was 1.00 (range: 0.75--1.39). The detection rate of PCa with TTSB was 48.1% (65/135 patients). Eight patients (5.9%) developed urinary retention after TTSB, and every patient was free from catheterization within 1 month after TTSB. No patient experienced a urinary tract infection ([Table 2](#t2-rru-9-187){ref-type="table"}). The detection rate of PCa in patients who had been diagnosed with HGPIN was 53% (9/17) and that in patients who had been diagnosed with HGPIN with two or more cores was 89% (8/9). The detection rate of PCa in patients who had been diagnosed with ASAP was 83% (10/12).

Analysis of factors that predict PCa on TTSB
--------------------------------------------

In the multivariate analysis, the factors that predicted PCa on TTSB were high age (odds ratio \[OR\]: 3.99, 95% confidence interval \[CI\]: 1.55--10.3), high PSA density (OR: 6.89, 95% CI: 2.62--18.2), low prostate volume (OR: 0.24, 95% CI: 0.09--0.63), two or more cores of HGPIN on the last biopsy (OR: 22.9, 95% CI: 2.27--230), and the findings of ASAP at the last biopsy (OR 14.7, 95% CI 2.35--91.6). Repeated TTSB significantly identified PCa in patients diagnosed with two or more cores of HGPIN and ASAP but not in patients diagnosed benign on previous TRUS-guided biopsy ([Table 3](#t3-rru-9-187){ref-type="table"}).

Pathological features of patients who were diagnosed with PCa
-------------------------------------------------------------

In the patient group whose condition was diagnosed as benign on previous TRUS-guided biopsies, the numbers of patients with 1, 2--5, 6--9, and 10 or more positive cores were 11/45 (24%), 20/45 (44%), 8/45 (18%), and 6/45 (13%), respectively. The numbers of patients with a GS of 6, 7, 8, and 9 were 11/45 (24%), 26/45 (58%), 5/45 (11%), and 3/45 (7%), respectively. The rate of significant cancer was 84% (38/45 patients) ([Table 4](#t4-rru-9-187){ref-type="table"}).

In the patient group with two or more cores of HGPIN at the last TRUS-guided biopsies, the numbers of patients with 1, 2--5, 6--9, and 10 or more positive cores were 3/8 (38%), 4/8 (50%), 1/8 (12%), and 0/8 (0%), respectively. The numbers of patients with a GS of 6, 7, 8, and 9 were 6/8 (75%), 1/8 (13%), 0/8 (0%), and 1/8 (13%), respectively. The rate of significant cancer was 63% (5/8 patients) ([Table 4](#t4-rru-9-187){ref-type="table"}).

In the patient group with ASAP at the last TRUS-guided biopsies, the numbers of patients with 1, 2--5, 6--9, and 10 or more positive cores were 3/10 (30%), 5/10 (50%), 2/10 (20%), and 0/10 (0%), respectively. The numbers of patients with a GS of 6, 7, 8, and 9 were 2/10 (20%), 8/10 (80%), 0/10 (0%), and 0/10 (0%), respectively. The rate of significant cancer was 80% (8/10 patients) ([Table 4](#t4-rru-9-187){ref-type="table"}).

The GS in patients whose condition was diagnosed as benign on previous TRUS-guided biopsies was significantly higher (*P*=0.02) than that of patients with two or more cores of HGPIN. The proportion of significant cancer was not significantly lower (*P*=0.09) in patients with two or more cores of HGPIN than in those with a benign diagnosis on previous TRUS-guided biopsies. The GS (*P*=0.49) or the proportion of significant cancer (*P*=0.75) in patients with a benign diagnosis on previous TRUS-guided biopsies was not significantly different from that of patients who were diagnosed with ASAP on previous TRUS-guided biopsies ([Table 4](#t4-rru-9-187){ref-type="table"}).

Discussion
==========

In this study, we evaluated whether HGPIN and ASAP at a previous biopsy were positive predictors of PCa on TTSB that was aimed at sampling one core for each 1 mL of prostate volume. We found that two or more cores of HGPIN at a previous TRUS-guided biopsy were positive predictors of PCa. Recently, some reports have shown that extensive HGPIN was a significant predictive factor of PCa at repeat biopsy, comparable to the results of our study.[@b9-rru-9-187],[@b10-rru-9-187],[@b23-rru-9-187] Based on these facts, two or more cores of HGPIN on a TRUS-guided biopsy with 10 or 12 cores strongly indicate the presence of PCa. Furthermore, the detection rate (88.9%) of PCa at repeat biopsy in patients who had two or more cores of HGPIN at a previous TRUS-guided biopsy is higher than those of other reports (30.9%,[@b20-rru-9-187] 31.8%,[@b21-rru-9-187] and 40%[@b10-rru-9-187]). The high detection rate of PCa in the present study can be explained as follows. The first reason is selection bias, because all patients who were diagnosed as having ASAP or HGPIN at a previous TRUS-guided biopsy did not undergo TTSB. Second, we used a longer period (515 days) between the previous TRUS-guided biopsy and TTSB than that of other reports (153[@b21-rru-9-187], 228[@b20-rru-9-187], and 294[@b10-rru-9-187] days). Lefkowitz et al[@b22-rru-9-187] found that patients with HGPIN on the initial extended biopsy had a 2.3% incidence of cancer at 1 year on repeat extended biopsy and a rate of 25.8% at 3 years. Based on these results, the long period between the previous TRUS biopsy and TTSB in the present study may have increased the rate of PCa. The third reason is the higher number of biopsy cores per unit of prostate volume in the present study. The median number of biopsy cores per unit of prostate volume was one core/1 mL. This number is the highest among all reports about TTSB.[@b18-rru-9-187] Lee et al[@b20-rru-9-187] reported that a high number of cores predicts PCa in patients who were diagnosed with HGPIN at a previous biopsy. These facts may contribute to the high detection rate of PCa in patients who had two or more cores of HGPIN at a previous TRUS-guided biopsy.

Some reports indicate that PCa in patients with HGPIN on previous TRUS-guided biopsy is insignificant.[@b16-rru-9-187],[@b17-rru-9-187] Patel et al[@b16-rru-9-187] reported that 98% of patients with HGPIN at the initial biopsy demonstrated GS of either 3+3 (86%) or 3+4 (12%). In the present study, the rate of PCa (GS of 6, 7, and 8) in patients with HGPIN at a previous TRUS biopsy was 37.5%, 75%, and 12.5%, respectively, and the rate was significantly lower in these patients than in benign patients who underwent a previous TRUS-guided biopsy. This result is comparable with that of previous reports.[@b16-rru-9-187],[@b17-rru-9-187] Based on these results, patients with HGPIN seen on a previous TRUS-guided biopsy preceding a diagnosis of PCa usually show favorable pathology, even with saturation biopsy.

The detection rate of PCa on repeat saturation biopsy in patients with ASAP who underwent a previous biopsy ranges between 35.4% and 61.3%, and the presence of ASAP on previous TRUS-guided biopsies is a significant, positive predictor of PCa on a saturation biopsy.[@b23-rru-9-187]--[@b25-rru-9-187] In addition, in the present study, the frequency of diagnosing PCa was 83%, and the presence of ASAP at a previous biopsy was a significant, positive predictor of PCa on TTSB aimed at sampling one core for each 1 mL of prostate volume. This result is comparable with previous reports and shows that the findings of ASAP on prostate biopsy strongly indicate the presence of PCa. The detection rate of PCa in the present study was higher than those of other reports.[@b23-rru-9-187]--[@b25-rru-9-187] The reasons for the high positive rate in the present study are the same as those previously stated (selection bias, long time between previous TRUS-guided biopsy and TTSB, and the number of biopsy cores).

Leone et al reported that 69/89 (78%) patients who were diagnosed with PCa with the findings of ASAP at a previous biopsy had a GS of 3+3 or less, 15/89 (17%) had a GS of 7, and 6/89 (6%) had a GS ≥8--10.[@b17-rru-9-187] Chen et al reported that 11.8% of patients with ASAP at previous biopsies had a GS of 7 or greater.[@b26-rru-9-187] In the present study, the detection rates of significant PCa and GS of 6 and 7 in patients with ASAP at a previous TRUS-guided biopsy were 80%, 20%, and 80%, respectively, and the detection rate of significant cancer and each GS was not significantly lower than that in benign patients who underwent previous TRUS-guided biopsy. The detection rate of significant cancer and GS in the present study were higher than those in other studies. Furthermore, five patients (50%) had a GS of 4+3 in the present study. Although these discrepancies are difficult to explain, the small population and selection bias for TTSB may be the reason for a high rate of significant cancer and high GS.

The present study has several limitations. First, this was a retrospective study. Second, all patients who were diagnosed with HGPIN or ASAP with TRUS biopsy did not undergo TTSB. Although we offered TTSB to all patients who were considered to need a repeat prostate biopsy with a previous biopsy showing HGPIN and/or ASAP, 10 patients did not receive TTSB because they refused to undergo the procedure. Furthermore, the median time between the previous TRUS-guided biopsy and TTSB was much longer than 6 months. Most patients did not undergo TTSB within 6 months after a pre-TRUS biopsy due to their own choice, although American[@b14-rru-9-187] and European[@b15-rru-9-187] guidelines recommend immediate repeat biopsy within 3--6 months after an initial diagnosis of ASAP. The last limitation was the small number of patients who underwent radical prostatectomy. Although seven patients who were diagnosed with PCa underwent radical prostatectomy, and the GS for specimens from prostatectomy were accordant with the GS for TTSB, the number is very small. In future, comparing the results of TTSB with those of prostatectomy is needed to evaluate whether TTSB aimed at sampling one core for each 1 mL of prostate volume can precisely evaluate PCa.

Conclusion
==========

The findings of ASAP or two or more cores of HGPIN at a previous TRUS-guided biopsy strongly indicate the presence of PCa on TTSB with a high number of biopsy cores per unit of prostate volume.
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==========================================

The institutional review board (IRB) of the Nara Medical University approved this study. As the data for the study were obtained through retrospective chart review, a waiver of informed consent was approved by the IRB. Personal information linked to research subjects and donors was anonymized (when necessary, the information was labeled with an identifying code to make it possible to distinguish between the individuals). Then, de-identified patient data were analyzed.
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###### 

Patients' clinical and pathological features

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Diagnosis on previous biopsy\                                                                                    
                                                           Median (range) or n (%)                                                                                          
  -------------------------------------------------------- ------------------------------- -------------- -------------------------------------------------- -------------- ---------------------------------------------------
  Age, years                                               70\                             63\            0.06[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   70\            0.67[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (47--83)                        (48--74)                                                          (37--75)       

  No. of previous TRUS biopsies                            1\                              1\             0.98[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   1\             0.53[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (1--5)                          (1--4)                                                            (1--2)         

  No. of cores obtained from the last TRUS-guided biopsy   10\                             12\            0.04[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   12\            0.004[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (8--13)                         (8--12)                                                           (8--13)        

  Time from the last TRUS-guided biopsy to TTSB, days      651\                            534\           0.19[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   515\           0.42[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (84--3522)                      (69--2332)                                                        (57--1263)     

  PSA, ng/mL                                               9.7\                            7.1\           0.04[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   7.0\           0.003[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (1.9--107)                      (4.2--17.5)                                                       (4.5--36.7)    

  PSA density, ng/mL/mL                                    0.26\                           0.19\          0.50[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   0.17\          0.47[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (0.06--1.9)                     (0.13--0.58)                                                      (0.08--0.57)   

  PSA velocity, ng/mL/year                                 1.2\                            0.89\          0.35[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   0.36\          0.02[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (−29--182)                      (−2.4--3.2)                                                       (−29--25)      

  DRE, abnormal findings                                   17\                             3\             0.39[\*](#tfn1-rru-9-187){ref-type="table-fn"}     3\             0.89[\*](#tfn1-rru-9-187){ref-type="table-fn"}
                                                           (16.1)                          (25.0)                                                            (16.7)         

  TRUS, abnormal findings                                  23\                             2\             0.72[\*](#tfn1-rru-9-187){ref-type="table-fn"}     3\             0.66[\*](#tfn1-rru-9-187){ref-type="table-fn"}
                                                           (21.9)                          (16.7)                                                            (16.7)         

  Prostate volume, mL                                      38.7\                           30.5\          0.10[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   46\            0.48[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (18--76.7)                      (20--57)                                                          (25--65)       

  Two or more cores HGPIN on the last biopsy               --                              --                                                                9\             
                                                                                                                                                             (50.0)         

  No. of cores obtained from TTSB                          36\                             33\            0.33[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}   41\            0.51[\*\*](#tfn2-rru-9-187){ref-type="table-fn"}
                                                           (16--75)                        (18--62)                                                          (23--54)       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Chi-square test,

Mann--Whitney *U* test.

**Abbreviations:** ASAP, atypical small acinar proliferation; HGPIN, high-grade prostatic intraepithelial neoplasia; TRUS, transrectal ultrasound; TTSB, transperineal template saturation biopsy; PSA, prostate-specific antigen; DRE, digital rectal examination.

###### 

TTSB results

                                        Median (range) or n (%)
  ------------------------------------- -------------------------
  No. of cores on TTSB                  37 (16--75)
  Core/volume, cores/mL                 1.00 (0.75--1.39)
  Urinary tract infection               0 (0)
  Retention                             8 (5.9)
  No. of patients with positive cores   65 (48.1)

**Abbreviation:** TTSB, transperineal template saturation biopsy.

###### 

Univariate and multivariate analyses of factors that positively predict prostate cancer

  -----------------------------------------------------------------------------------------------------------------------
  Variables/Categories                            Univariate analysis\   *P*-value   Multivariate analysis\   *P*-value
                                                  OR (95% CI)                        OR (95% CI)              
  ----------------------------------------------- ---------------------- ----------- ------------------------ -----------
  Age (years)                                                                                                 

   ≤70.1                                          (Ref)                              (Ref)                    

   \>70.1                                         3.50 (1.71--7.16)      \<0.01      3.99 (1.55--10.3)        0.004

  No. of TRUSB                                                                                                

   =1                                             (Ref)                                                       

   \>1                                            0.87 (0.37--2.07)      0.76                                 

  No. cores obtained by last TRUS-guided biopsy                                                               

   ≤10                                            (Ref)                                                       

   \>10                                           1.38 (0.68--2.79)      0.37                                 

  PSA (ng/mL)                                                                                                 

   ≤10.9                                          (Ref)                                                       

   \>10.9                                         1.91 (0.95--3.84)      0.07                                 

  PSA density (ng/mL/mL)                                                                                      

   ≤0.28                                          (Ref)                              (Ref)                    

   \>0.28                                         5.2 (2.45--11.0)       \<0.01      6.89 (2.62--18.2)        \<0.001

  PSA velosity (ng/mL/year)                                                                                   

   ≤1.2                                           (Ref)                                                       

   \>1.2                                          1.91 (0.95--3.81)      0.07                                 

  DRE                                                                                                         

   Benign                                         (Ref)                                                       

   Suspicious                                     2.20 (0.86--5.62)      0.09                                 

  TRUS                                                                                                        

   Benign                                         (Ref)                              (Ref)                    

   Suspicious                                     2.72 (1.12--6.58)      0.03        1.57 (0.45--4.82)        0.53

  Prostate volume (mL)                                                                                        

   ≤34.1                                          (Ref)                              (Ref)                    

   \>34.1                                         0.21 (0.09--0.43)      \<0.01      0.24 (0.09--0.63)        0.004

  HGPIN on the last biopsy                                                                                    

   Benign                                         (Ref)                                                       

   Present                                        1.47 (0.55--3.92)      0.43                                 

  Two or more cores HGPIN on the last biopsy                                                                  

   Benign                                         (Ref)                              (Ref)                    

   Present                                        9.08 (1.10--74.7)      0.04        22.9 (2.27--230)         0.008

  ASAP on the last biopsy                                                                                     

   Benign                                         (Ref)                              (Ref)                    

   Present                                        5.78 (1.21--27.5)      0.03        14.7 (2.35--91.6)        0.004
  -----------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ASAP, atypical small acinar proliferation; HGPIN, high-grade prostatic intraepithelial neoplasia; TRUS, transrectal ultrasound; TRUSB, transrectal ultrasound-guided biopsy; TTSB, transperineal template saturation biopsy; PSA, prostate-specific antigen; DRE, digital rectal examination.

###### 

The number of positive cores and cancer grade

                              Findings at a previous biopsy                                                          
  --------------------------- ------------------------------- ------------------------------------------------------ ------------------------------------------------------
  Positive on TTSB            45 (43)                         10 (83)                                                8 (89)
  No. of positive cores                                       *P*=0.66[\*](#tfn6-rru-9-187){ref-type="table-fn"}     *P*=0.60[\*](#tfn6-rru-9-187){ref-type="table-fn"}
   1                          11 (24)                         3 (30)                                                 3 (38)
   2--5                       20 (44)                         5 (50)                                                 4 (50)
   6--9                       8 (18)                          2 (20)                                                 1 (12)
   ≥10                        6 (13)                          0                                                      0
  Gleason score                                               *P*=0.49[\*](#tfn6-rru-9-187){ref-type="table-fn"}     *P*=0.02[\*](#tfn6-rru-9-187){ref-type="table-fn"}
   6                          11 (24)                         2 (20)                                                 6 (75)
   7                          26 (58)                         8 (80)                                                 1 (13)
   8                          5 (11)                          0                                                      0
   9                          3 (7)                           0                                                      1 (13)
  Maximum tumor length (mm)                                   *P*=0.06[\*\*](#tfn7-rru-9-187){ref-type="table-fn"}   *P*=0.36[\*\*](#tfn7-rru-9-187){ref-type="table-fn"}
  9 (1--20)                   4 (1--10)                       7 (1--14)                                              
  Total tumor length (mm)                                     *P*=0.17[\*\*](#tfn7-rru-9-187){ref-type="table-fn"}   *P*=0.37[\*\*](#tfn7-rru-9-187){ref-type="table-fn"}
  20 (1--170)                 8 (2--23)                       16 (1--14)                                             
  Significant cancer                                          *P*=0.75[\*](#tfn6-rru-9-187){ref-type="table-fn"}     *P*=0.09[\*](#tfn6-rru-9-187){ref-type="table-fn"}
  38 (84)                     8 (80)                          5 (63)                                                 

**Notes:**

Chi-square test;

Mann--Whitney *U* test.

**Abbreviations:** HGPIN, high-grade prostatic intraepithelial neoplasia; ASAP, atypical small acinar proliferation; TTSB, transperineal template saturation biopsy.
